|
01 Oct 2025 |
Jubilant Pharmova
|
Consensus Share Price Target
|
1079.40 |
1357.00 |
- |
25.72 |
buy
|
|
|
|
|
26 May 2016
|
Jubilant Pharmova
|
ICICI Securities Limited
|
1079.40
|
405.00
|
352.25
(206.43%)
|
|
Hold
|
|
|
ICICI Securities Ltd | Retail Equity Research Revenues de-grew 2.3% YoY to | 1501 crore (I-direct estimate: | 1500 crore). Revenues in the pharmaceutical business grew 10.1%...
|
|
31 Mar 2016
|
Jubilant Pharmova
|
GEPL Capital
|
1079.40
|
501.00
|
416.35
(159.25%)
|
Target met |
Buy
|
|
|
Jubilant Life Sciences Limited (JOL) is an integrated global pharmaceutical and life sciences company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products, Advance Intermediates, Fine Ingredients, Crop Science Ingredients, Life Science Chemicals and Nutritional Products. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery Solutions. The...
|
|
03 Nov 2015
|
Jubilant Pharmova
|
ICICI Securities Limited
|
1079.40
|
460.00
|
427.25
(152.64%)
|
|
Hold
|
|
|
|
|
30 Oct 2015
|
Jubilant Pharmova
|
Karvy
|
1079.40
|
447.00
|
409.55
(163.56%)
|
|
Hold
|
|
|
Specialty pharmaceutical drives growth in Pharma: The company reported revenue growth of 22% YoY in pharmaceuticals with specialty, covering radio-pharmaceuticals, and APIs leading the growth. The revenue growth across geographies was also robust. The company is now deriving 89% of revenues from regulated markets in Pharma.
|
|
22 Aug 2015
|
Jubilant Pharmova
|
Karvy
|
1079.40
|
447.00
|
369.15
(192.40%)
|
Target met |
Buy
|
|
|
Jubilant Life Sciences operating in pharmaceuticals and life sciences division, has restored operations in CMO facility after clearing the FDA inspection issues. As the new product launches and recovery in margins are expected, the company has set itself a renewed growth path in the medium term.
|
|
15 Apr 2015
|
Jubilant Pharmova
|
Phillip Capital
|
1079.40
|
|
172.55
(525.56%)
|
|
|
|
|
business progress and to get an update on its facility issues. JOL is an integrated global pharma company with 53% revenue flowing from pharmaceuticals and 47% from Life scienceingredients.UnderPharma,itmanufactures/suppliesbulkingredients,formulations,...
|
|
25 Oct 2013
|
Jubilant Pharmova
|
Ajcon Global
|
1079.40
|
176.00
|
103.10
(946.94%)
|
Target met |
Buy
|
|
|
Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Generics, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world- class manufacturing facilities in India, US and Canada and a team of...
|